SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Array Biopharma, Inc
An SI Board Since March 2005
Posts SubjectMarks Bans Symbol
321 29 0 ARRY
Emcee:  keokalani'nui Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
246Certain that there are lurkers here who also are appreciative, thanks! Let me scaram(o)uche-3/23/2013
245AZN Investor Day Slides (comments): siliconinvestor.com . mcbio-3/22/2013
244ARRY @ Cowen (more buzz for selumetinib moving to P3): siliconinvestor.com .mcbio-3/7/2013
243Yeah, of course. But I was looking from the view of having dissed 520 as I was wscaram(o)uche-3/1/2013
242New MEK162 study (uveal melanoma; single-agent selumetinib has had strong resultmcbio-3/1/2013
241Well, it's only the correct decision when you sell and actually realize the mcbio-3/1/2013
240and the appreciation since I bailed! Frustrated, you clearly made the correctscaram(o)uche-3/1/2013
239Sally Church on ARRY-520: pharmastrategyblog.com .mcbio-3/1/2013
238Clin Cancer Res. 2013 Feb 26. [Epub ahead of print] Phase II trial of MEK inhiscaram(o)uche-3/1/2013
237Chuckle. Now that you mentioned ct.gov, I do remember having found this dead enscaram(o)uche-2/28/2013
236Interesting. But, it looks like that was completed awhile ago and there are no mcbio-2/27/2013
235Didn't have a clue that this second molecule was in clinical testing (emphasscaram(o)uche-2/27/2013
234Thanks! I appreciate it. Certainly willing to hold for all of this year if neemcbio-2/6/2013
233I hung in there for a loooooooong time, and I kept a small position. Pulling foscaram(o)uche-2/6/2013
232I actually tend to agree with your skeptical take on the CC. I am just going tomcbio-2/6/2013
231>> Good presentation << Squarer is such a pumper. I like that, excscaram(o)uche-2/6/2013
230Thanks, though I don't think I can take the credit. I also contacted ARRY (mcbio-2/4/2013
229I see it had the desired effect, good job. I don't follow the company as mutuck-2/4/2013
228I think it's a BS Bloomberg article and have contacted both the author and emcbio-2/3/2013
227There's discussion of this over at Dew's. I'm sure you know this butom pope-2/3/2013
226But hearing this doesn't quite gybe with the slides shown during the quartertuck-2/3/2013
225"AstraZeneca has ended nine drug development programs since June 30, includtuck-2/3/2013
224Hopefully the poster will show actual PFS data from the trial (appears that was mcbio-1/23/2013
223Thank you! Rickscaram(o)uche-1/23/2013
222Selumetinib+irinotecan in KRAS CRC ASCO GI abstract now up. See: asco.org.mcbio-1/22/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News